Patents by Inventor Michael Kinch

Michael Kinch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8796423
    Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: August 5, 2014
    Assignee: Eli Lilly and Company
    Inventors: Limin Li, Michael Kinch, Michael Goldbiatt
  • Patent number: 8207209
    Abstract: A method of inhibiting viral respiratory infection in a mammal in need of same, includes administering an effective amount of 2-[2-(5-carbamimidoyl-benzofuran-2-yl)-vinyl]-H-benzoimidazole-5-carboxamidine or the Bis-N-hydroxyamidine prodrug thereof, prior to viral infection, or therapeutically following viral infection, to inhibit that viral infection. The compound selectively inhibits Caspase 2 and/or 8 as to prevent infective viral particle release. It is optionally administered IV, IP, orally or via other conventional administration routes in a dosage range of 1 ng/kg-200 mg/kg of body weight.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: June 26, 2012
    Assignee: Functional Genetics, Inc.
    Inventors: Michael Kinch, Michael Goldblatt
  • Publication number: 20120142731
    Abstract: Compounds, pharmaceutical compositions and methods of inhibiting viral infection in a mammal in need of same, are provided, which employ compounds of the formula wherein each X is independently H or an electrodonating group, each Y is independently H, alkyl of 1-4 carbon atoms, hydroxy, alkoxy or methylene and wherein Substituent Z is a di-or-tri akly amino, or alkyl di or tri amino, optionally substituted with a halogen moiety. This family of compounds, designated FGI-104 herein, inhibits viral infection therapeutically and prophylactically.
    Type: Application
    Filed: October 30, 2008
    Publication date: June 7, 2012
    Applicant: Functional Genetics, Inc.
    Inventors: Michael Kinch, Michael Goldblatt
  • Publication number: 20110287019
    Abstract: The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein like Tsg101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse.
    Type: Application
    Filed: June 13, 2011
    Publication date: November 24, 2011
    Applicant: FUNCTIONAL GENETICS, INC.
    Inventors: ROXANNE DUAN, MICHAEL KINCH, MICHAEL GOLDBLATT
  • Publication number: 20110206695
    Abstract: XMRV appears to be related to both prostate cancer if it infects a male germ cell and chronic fatigue syndrome in both sexes. (If the virus does not infect a germ cell). Prostate cancer cells exhibit TSG101 on the surface only upon infection with a virus like XMRV. Antibodies to TSG101 can be effective diagnostics to identify individuals with a predisposition to prostate. They can also be used in place of current diagnostics to confirm the presence of prostate cancer. TSG101 antibodies, when administered in vivo, exhibit the ability to reduce tumor size, suppress metastatic transformation and extend survival.
    Type: Application
    Filed: January 25, 2011
    Publication date: August 25, 2011
    Applicant: FUNCTIONAL GENETICS, INC.
    Inventors: Manu Kohli, Michael Goldblatt, Michael Kinch
  • Patent number: 7981410
    Abstract: The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein likeTsg 101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: July 19, 2011
    Assignee: Functional Genetics, Inc.
    Inventors: Roxanne Duan, Michael Kinch, Michael Goldblatt
  • Publication number: 20110152343
    Abstract: Caspace inhibition provides inhibition of viral infection across a wide collection of caspaces and viruses. Caspace inhibition, the prevention of the formation of active caspaces, can be achieved either through gene therapy, protein binding an inhibition, or through small molecule administration. Examples for small molecule inhibition allow the formation of a pharmacaphore to identify more and more active small molecules.
    Type: Application
    Filed: December 22, 2009
    Publication date: June 23, 2011
    Applicant: Functional Genetics, Inc.
    Inventors: M. JAVAD AMAN, Michael Kinch, Sven Enterlein, Yunus Abdul
  • Patent number: 7964708
    Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: June 21, 2011
    Inventors: Limin Li, Michael Kinch, Michael Goldblatt, Roxanne Duan
  • Publication number: 20100286248
    Abstract: A human gene, fg01, on chromosome 8, is identified. This gene, and its expression product, human fg01, shares a homology under 70% with the corresponding murine gene, which has been linked to presentation of the Alzheimer's phenotype of A? plaques and hyperphosphorylated tau tangles. Upregulation appears to suppress the Alzheimer's phenotype, which may be effective in preventing the onset of symptoms or progression of symptoms associated with AD. Screening methods are also set forth.
    Type: Application
    Filed: September 25, 2009
    Publication date: November 11, 2010
    Applicant: Functional Genetics, Inc.
    Inventors: WU-BO LI, MICHAEL KINCH, MICHAEL GOLDBLATT
  • Publication number: 20100286252
    Abstract: A human gene, fg01, on chromosome 8, is identified, as well as a truncated form on chromosome 5. Upregulation appears to suppress the Alzheimer's phenotype, (AB plaques and hyperphosphorylated tau tangles) which may address the onset of symptoms or progression of symptoms associated with AD. Screening methods are also set forth.
    Type: Application
    Filed: May 10, 2010
    Publication date: November 11, 2010
    Applicant: Functional Genetics, Inc.
    Inventors: Wu-Bo LI, Michael Kinch, Michael Goldblatt
  • Publication number: 20090285819
    Abstract: Genes relating to resistance to infection by influenza virus are identified. The genes and the gene products (i.e., the polynucleotides transcribed from and polypeptides encoded by the genes) can be used for the prevention and treatment of influenza. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products.
    Type: Application
    Filed: November 15, 2007
    Publication date: November 19, 2009
    Applicant: Functional Genetics, Inc.
    Inventors: Limin Li, Michael Kinch, Michael Goldblatt
  • Publication number: 20090220527
    Abstract: The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: December 20, 2006
    Publication date: September 3, 2009
    Applicant: MEDLMMUNE, LLC
    Inventors: Melissa Damschroder, William Dall'Acqua, Herren Wu, Michael Kinch
  • Publication number: 20090186041
    Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
    Type: Application
    Filed: April 18, 2008
    Publication date: July 23, 2009
    Applicant: Functional Genetics, Inc.
    Inventors: LIMIN LI, Michael Kinch, Michael Goldbiatt
  • Publication number: 20090170890
    Abstract: A method of inhibiting viral infection in a mammal in need of same, includes administering an effective amount of at least one of the compounds of FGI-103 which are represented by 273, 365 and 510 either prophylactically to prevent viral infection, or therapeutically following viral infection. These compounds appear to selectively inhibit Caspase 8 as a method of preventing infective viral particle release. They can be administered IV, IP, orally or via other conventional administration routes. The compounds are highly effective, requiring relatively low dosages on the order of 1 ng/kg-200 mg/kg of body weight.
    Type: Application
    Filed: October 23, 2008
    Publication date: July 2, 2009
    Applicant: FUNCTIONAL GENETICS, INC.
    Inventors: Michael Kinch, Michael Goldblatt
  • Publication number: 20080187528
    Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
    Type: Application
    Filed: November 15, 2007
    Publication date: August 7, 2008
    Applicant: Functional Genetics, Inc.
    Inventors: Limin Li, Michael Kinch, Michael Goldblatt
  • Publication number: 20080149808
    Abstract: A building structure formed of concrete and including dams to form raised structures on the roof and a method of overturning the concrete mold.
    Type: Application
    Filed: December 20, 2006
    Publication date: June 26, 2008
    Applicant: CANADIAN ROCKPORT HOMES LTD.
    Inventors: William Raymond MALONE, Chris Michael KINCH, Kenneth Oscar OLSEN, Herman Pablo ROSEN SAGREDO
  • Publication number: 20080124341
    Abstract: The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein likeTsg 101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse.
    Type: Application
    Filed: November 13, 2007
    Publication date: May 29, 2008
    Applicant: Functional Genetics, Inc.
    Inventors: Roxanne Duan, Michael Kinch, Michael Goldblatt
  • Publication number: 20080089931
    Abstract: The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase (“LMW-PTP”) in particular using moieties that bind an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, and inhibits or reduces LMW-PTP expression and/or activity. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more agents that inhibit LMW-PTP expression and/or activity operatively associated with the delivery vehicle.
    Type: Application
    Filed: December 10, 2007
    Publication date: April 17, 2008
    Applicant: MedImmune, Inc.
    Inventor: Michael Kinch
  • Publication number: 20080044413
    Abstract: The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs.
    Type: Application
    Filed: December 21, 2006
    Publication date: February 21, 2008
    Inventors: Scott Hammond, Peter Kiener, Elizabeth Bruckheimer, Michael Kinch, Shannon Roff, Ralf Lutterbuese, Petra Lutterbuese, Bernd Schlereth, Patrick Baeuerle, Peter Kufer
  • Publication number: 20080003210
    Abstract: The present invention relates to novel non-human primate receptor tyrosine kinases. In particular, the present invention relates to Rhesus EphA2 and Cynomolgus EphA2 nucleotide and amino acid sequences.
    Type: Application
    Filed: March 12, 2007
    Publication date: January 3, 2008
    Applicant: MedImmune, Inc.
    Inventors: Elizabeeth Bruckheimer, William Walsh, Michael Kinch